erlotinib hydrochloride has been researched along with Recrudescence in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 17 (85.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou Dalle, I; Alvarado, Y; Borthakur, G; Cortes, JE; Diaz Duque, A; Estrov, Z; Ferrajoli, A; Gandhi, V; Jabbour, E; Kantarjian, HM; Konopleva, M; Lamothe, B; Pemmaraju, N; Pinnamaneni, P; Randhawa, J; Ravandi, F; Wierda, WG | 1 |
| Aerts, JG; Biesma, B; Burgers, S; Codrington, H; Dalesio, O; Dingemans, AM; Groen, HJ; Lankheet, NA; Smit, EF; Vincent, AD | 1 |
| Bass, SA; Gibson, AM; Khurana Hershey, GK; Xiao, C; Zhang, Z | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Corbett, TB; Levine, MN; Okawara, G; Pond, GR; Sur, R; Swaminath, A; Tsakiridis, TK; Ung, YC; Wright, JR | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Murphy, M; Stordal, B | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Koshiishi, H; Takahashi, E; Takahashi, M | 1 |
| Arola, M; Kähkönen, M; Lohi, O; Parto, K; Vettenranta, K; Vornanen, M | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ | 1 |
| Sabbatini, P | 1 |
| Chen, E; Dancey, J; Hedley, D; Ho, J; Major, P; Moore, MJ; Nicklee, T; Oza, AM; Pond, GR; Siu, LL; Townsley, CA; Tsao, M | 1 |
1 review(s) available for erlotinib hydrochloride and Recrudescence
| Article | Year |
|---|---|
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
8 trial(s) available for erlotinib hydrochloride and Recrudescence
| Article | Year |
|---|---|
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Young Adult | 2018 |
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pemetrexed; Quinazolines; Recurrence; Taxoids | 2013 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Quality of Life; Recurrence; Survival Analysis; Thorax; Treatment Outcome | 2016 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence | 2012 |
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Recurrence; Risk Factors; Signal Transduction; Survival Rate; Treatment Outcome | 2006 |
11 other study(ies) available for erlotinib hydrochloride and Recrudescence
| Article | Year |
|---|---|
EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
Topics: Administration, Cutaneous; Allergens; Animals; Cells, Cultured; Chemokine CXCL1; Chemokine CXCL2; Dermatitis, Atopic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Interleukin-17; Interleukin-1beta; Interleukin-22; Interleukin-6; Interleukins; Keratinocytes; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Mutant Strains; Quinazolines; Recurrence; Signal Transduction; Skin; Specific Pathogen-Free Organisms; Th17 Cells | 2014 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].
Topics: Adult; Erlotinib Hydrochloride; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Recurrence; Thymoma; Thymus Neoplasms | 2011 |
Recurrent congenital fibrosarcoma with heart metastases.
Topics: Erlotinib Hydrochloride; Female; Fibrosarcoma; Heart Neoplasms; Humans; Infant; Oncogene Proteins, Fusion; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
New agents and new formulations for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A | 2005 |